As PRT543 was generally well tolerated by patients with recurrent/metastatic ACC [45], the anti-tumor activity of PRMT5 inhibitors may be further enhanced when given in combination with other therapeutic agents. Here, PRMT5 is linked to adrenal cortex carcinoma.